Gilead announces results from Phase 3 Study of Sofosbuvir among Hepatitis C patients in Japan

03-04-2014 Business Wire HealthComments (0)

BiotechnologyGilead SciencessofosbuvirUSA

Gilead Sciences (Nasdaq:GILD) today announced topline results from a Phase 3 clinical trial (Study GS-US-334-0118) in Japan evaluating the once-daily nucleotide analog polymerase inhibitor sofosbuvir in combination with ribavirin (RBV) for the treatment of genotype 2 chronic hepatitis C virus (HCV) infection. The study met its primary efficacy endpoint of superiority compared to a predefined historical control sustained virologic response (SVR) rate.

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top